These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33754222)

  • 21. Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.
    Ibáñez Vodnizza SE; Nurmohamed MT; Visman IM; van Denderen JC; Lems WF; Jaime F; van der Horst-Bruinsma IE
    J Rheumatol; 2017 Sep; 44(9):1355-1361. PubMed ID: 28711878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?
    Wroński J; Fiedor P
    J Clin Pharmacol; 2019 Apr; 59(4):445-462. PubMed ID: 30476367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.
    Sieper J; Appel H; Braun J; Rudwaleit M
    Arthritis Rheum; 2008 Mar; 58(3):649-56. PubMed ID: 18311819
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy of etanercept in ankylosing spondylitis hip lesions.
    Wang D; Ma L; Wu D
    Joint Bone Spine; 2011 Oct; 78(5):531-2. PubMed ID: 21570332
    [No Abstract]   [Full Text] [Related]  

  • 25. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
    Haraoui B; Krelenbaum M
    Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
    Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
    Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
    Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TNF antagonists for ankylosing spondylitis.
    Drug Ther Bull; 2005 Mar; 43(3):19-22. PubMed ID: 15762384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correspondence on 'Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence'.
    Zhang ZL; Huang W; Lv GH; Li J; Zou MX; Dai ZH
    Ann Rheum Dis; 2022 Dec; 81(12):e252. PubMed ID: 33004326
    [No Abstract]   [Full Text] [Related]  

  • 32. Response to 'Correspondence on "Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence" by Zhang
    Koo BS; Oh JS; Park SY; Shin JH; Ahn GY; Lee S; Joo KB; Kim TH
    Ann Rheum Dis; 2022 Dec; 81(12):e253. PubMed ID: 33004327
    [No Abstract]   [Full Text] [Related]  

  • 33. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
    van Weely SF; Kneepkens EL; Nurmohamed MT; Dekker J; van der Horst-Bruinsma IE
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1522-9. PubMed ID: 26881893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of genetic predisposition of de novo uveitis with etanercept in ankylosing spondylitis.
    Killian M; Touraine R; Amouzougan A; Thomas T; Marotte H
    Ann Rheum Dis; 2015 Mar; 74(3):e22. PubMed ID: 25467296
    [No Abstract]   [Full Text] [Related]  

  • 35. Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial.
    Yates M; Hamilton LE; Elender F; Dean L; Doll H; MacGregor AJ; Thomas J; Gaffney K
    J Rheumatol; 2015 Jul; 42(7):1177-85. PubMed ID: 26034151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete Remission of Nephrotic Syndrome Without Resolution of Amyloid Deposit After Anti-Tumor Necrosis Factor α Therapy in a Patient With Ankylosing Spondylitis.
    Lee YH; Kim EY; Jeong DW; Kim YG; Lee SH; Song R; Yang HI; Lim SJ; Moon JY; Lee SH
    J Clin Rheumatol; 2016 Mar; 22(2):86-8. PubMed ID: 26906302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis.
    van Sijl AM; van Eijk IC; Peters MJ; Serné EH; van der Horst-Bruinsma IE; Smulders YM; Nurmohamed MT
    Ann Rheum Dis; 2015 Jan; 74(1):119-23. PubMed ID: 24092419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid remission of treatment-resistant ankylosing spondylitis with etanercept--a drug for refractory ankylosing spondylitis?
    Barthel HR
    Arthritis Rheum; 2001 Aug; 45(4):404. PubMed ID: 11501730
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
    Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
    Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials.
    Baraliakos X; Koenig AS; Jones H; Szumski A; Collier D; Bananis E
    J Rheumatol; 2015 Aug; 42(8):1418-26. PubMed ID: 26077401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.